Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL708096 | 1.00 | CA14 (0.37) | CA14CA12CA1CA2CA7 | |
| SCHEMBL19663961 | 0.87 | CA14 (0.40) | CA14CA12CA1CA2CA7 | |
| SCHEMBL27309422 | 0.86 | NFKB1 (0.38) | CA1CA2CA7MEN1KMT2A | |
| SCHEMBL22170044 | 0.83 | SMN1; SMN2 (0.35) | CA14CA12CA1CA2MEN1 | |
| SCHEMBL3193193 | 0.82 | MEN1 (0.34) | CA14CA12CA1CA2CA7 | |
| SCHEMBL1163137 | 0.82 | MEN1 (0.34) | CA14CA12CA1CA2CA7 | |
| SCHEMBL3158882 | 0.82 | MEN1 (0.34) | CA14CA12CA1CA2CA7 | |
| SCHEMBL14370031 | 0.82 | CA14 (0.35) | CA14CA12CA1CA2CA7 | |
| SCHEMBL2153085 | 0.82 | CA14 (0.35) | CA14CA12CA1CA2CA7 | |
| SCHEMBL29023150 | 0.82 | CA14 (0.35) | CA14CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187497-B2 | Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP) | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9187497-B2 | Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP) | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9187497-B2 | Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP) | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150031652-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20150031652-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20150031652-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-8822470-B2 | Substituted pyrido[2,3-b]pyrazines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822470-B2 | Substituted pyrido[2,3-b]pyrazines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822470-B2 | Substituted pyrido[2,3-b]pyrazines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130274239-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-10-17 | — | — | US | disclosed |
| US-20110158989-A1 | Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-7928105-B2 | Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7928105-B2 | Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7928105-B2 | Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-19 | — | — | US | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085570-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085570-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | WO | disclosed |
| EP-1268525-B1 | MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING N-CYCLIC P2 MOIETIES | SCHERING CORP (US) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | CA14 4821/4885CA12 4828/4885CA1 4674/4885 |
| US-20110158989-A1 | Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS | PARP1, PARP3, PARP2 | CA14 4821/4885CA12 4828/4885CA1 4674/4885 |
| US-20150031652-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP3, PARP2 | CA14 4821/4885CA12 4828/4885CA1 4674/4885 |
| US-20130274239-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP3, PARP2 | CA14 4821/4885CA12 4828/4885CA1 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.